I spent yesterday afternoon at the Forum for Medical Innovation in downtown Chicago, hosted by the Council for American Medical Innovation and moderated by former U.S. House of Representatives majority leader Dick Gephardt. The event also featured AstraZeneca CEO David Brennan as a guest speaker. [img_assist|nid=1172|title=David Brennan|desc=|link=none|align=right|width=128|height=86]

From Chemical Engineering Progress, Girish Malhotra presents his prescription for the pharmaceutical industry----QbD, PAT and control all play a key role, and chemical engineers will make it happen. The ultimate goal will be entirely new business models for pharma.

A nice, if brief, Q&A appeared today in India's Business Standard, featuring a conversation with Arun Kumar, CEO of generics maker Strides Arcolab.

At a meeting at DIA in Boston yesterday, Mike Svinte, President of Global Life Sciences at IBM provided a sneak peek and insights into a new report probing CEO challenges and concerns and their implications. The report, which is due to be released next month, will distill interviews with more...

This afternoon, the Senate will vote on sweeping patent reform measures that are pleasing tech companies but worrying pharma and biopharma (more on this from the Houston Chronicle). Read a report The Department of Justice and FTC released a comprehensive report on the subject this morning, while Bloomberg's Washington correspondent...